You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,206,448


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,206,448
Title:Injection of fibrin sealant using reconstituted components in spinal applications
Abstract: A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, wherein the fibrinogen, the activating compound or both has been reconstituted with a solution containing at least one additive, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc.
Inventor(s): Burkinshaw; Brian D. (Pflugerville, TX), Whitlock; Steven I. (Austin, TX), Pauza; Kevin (Tyler, TX), Richards; Mark I. (Leander, TX), Rogan; James B. (Austin, TX)
Assignee: Spinal Restoration, Inc. (Austin, TX)
Application Number:11/205,784
Patent Claims:1. A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus, comprising: injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and thrombin, wherein at least a portion of the fibrin forms after injection, wherein the fibrinogen, the thrombin or both has been reconstituted with a solution containing at least one additive, wherein a corticosteroid is absent from the fibrin sealant injected into the disc, and wherein the injecting occurs by inserting an introducer needle having a tip into the intra-discal space to a position adjacent to the at least one defect, inserting a second needle or a polymeric catheter through the introducer needle up to but not beyond the tip of the introducer needle, and injecting the fibrin sealant through the second needle or polymeric catheter.

2. The method of claim 1, wherein neither the nucleus pulposus nor the annulus fibrosus has been heated.

3. The method of claim 1, wherein the fibrin sealant consists essentially of fibrinogen, thrombin and the at least one additive, and optionally calcium chloride.

4. The method of claim 1, wherein the fibrin sealant consists of fibrinogen, thrombin, and the at least one additive, and optionally containing calcium chloride.

5. The method of claim 1, wherein the fibrin sealant further comprises calcium chloride which is injected with the fibrinogen and the activating compound.

6. The method of claim 1, wherein the method consists of the injecting step.

7. The method of claim 1, wherein the additive is selected from the group consisting of antibiotics; antiproliferative, cytotoxic, and antitumor drugs including chemotherapeutic drugs; analgesic; antiangiogen; antibody; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; anesthetics; analgesics; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; peptides including polypeptides and proteins; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts and derivatives thereof; polysaccharides; cellulose compounds and derivatives thereof; gene therapy reagents; genetically altered cells, stem cells including mesenchymal stem cells with transforming growth factor, and/or other cells; cell growth factors; type II collagen; elastin; sulfated glycosaminoglycan (sGAG), glucosamine sulfate; pH modifiers; methylsulfonylmethane (MSM); osteogenic compounds; osteoconductive compounds; plasminogen; nucleotides; oligonucleotides; polynucleotides; polymers; osteogenic protein 1 (oP-1 including recombinant OP-1); LMP-1 (Lim Mineralization Protein-1); cartilage; oxygen-containing components; enzymes; melatonin; vitamins; and nutrients.

8. The method of claim 1, wherein at least one additive is a local anesthetic.

9. The method of claim 1, wherein no portion of the nucleus pulposus has been removed by surgery.

10. The method of claim 1, wherein the at least one defect is a tear or fissure in the annulus fibrosus.

11. The method of claim 1, wherein normal hydrostatic pressure in the disc is restored or normal disc height is restored or both.

12. The method of claim 1, wherein the fibrinogen is autologous.

13. The method of claim 1, wherein the injection is performed using a dual barrel syringe.

14. The method of claim 1, wherein a mixture of fibrinogen and thrombin is injected.

15. The method of claim 1, wherein the fibrinogen and thrombin are injected sequentially and at least partially mix in the disc.

16. The method of claim 1, wherein the additives are injected sequentially either before with or after the fibrinogen and thrombin and at least partially mix in the disc.

17. The method of claim 1, wherein the disc is injected with the fibrin sealant at multiple points.

18. The method of claim 1, wherein the disc is a lumbar disc.

19. The method of claim 1, wherein the disc is a cervical disc.

20. The method of claim 1, wherein the disc is a thoracic disc.

21. The method of claim 1, wherein a contrast agent is injected either before the fibrin sealant, with the fibrin sealant, or after the fibrin sealant has been injected.

22. A kit, comprising: fibrinogen, thrombin, at least one additive, a first needle having a tip, a spinal needle having a tip or a polymeric catheter having a tip or both a spinal needle and a polymeric catheter, wherein the length of the spinal needle and polymeric catheter is configured such that the tip of the spinal needle and the tip of the polymeric catheter do not extend past the tip of the first needle during use, wherein the kit excludes corticosteroid and wherein the kit excludes a device to provide thermal energy to a disc.

23. A process for manufacturing a kit, comprising: providing a fibrinogen component, a thrombin component, at least one additive, a first needle having a tip, and a spinal needle having a tip or a polymeric catheter having a tip or both a spinal needle and a polymeric catheter, wherein the length of the spinal needle and polymeric catheter is configured such that the tip of the spinal needle and the tip of the polymeric catheter do not extend past the tip of the first needle during use, wherein the kit excludes corticosteroid and wherein the kit excludes a device to provide thermal energy to a disc.

24. A method of treating a disc having an intra-discal space, comprising: percutaneously inserting an introducer needle having a tip into the intra-discal space, inserting a second needle through the introducer needle up to but not beyond the tip of the introducer needle, and injecting a fibrin sealant into the disc, wherein the fibrin sealant comprises fibrinogen, thrombin, and an additive, wherein at least a portion of the fibrin forms after injection, and wherein a corticosteroid is absent from the fibrin sealant injected into the disc.

25. The method of claim 24, wherein the injecting occurs by injecting the fibrin sealant through the second needle or polymeric catheter.

26. The method of claim 1, wherein the only thrombin injected is the reconstituted thrombin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.